Investors were feeling a little calmer on Friday after a batch of solid tech earnings. The Cboe Volatility Index, a widely followed gauge of fear and uncertainty that trades under the ticker VIX, slid by 0.
Investors were feeling a little calmer on Friday after a batch of solid tech earnings. The Cboe Volatility Index, a widely followed gauge of fear and uncertainty that trades under the ticker VIX, slid by 0.
(RTTNews) - French stocks drifted lower on Friday amid rising concerns about Middle East tensions. With the Strait of Hormuz remaining effectively closed, oil prices climbed higher, raising worries about inflation and possible monetary tightening by central banks.
(RTTNews) - French stocks drifted lower on Friday amid rising concerns about Middle East tensions. With the Strait of Hormuz remaining effectively closed, oil prices climbed higher, raising worries about inflation and possible monetary tightening by central banks.
Michael Vi/iStock Editorial via Getty Images The U.S. Food and Drug Administration (FDA) has declined to approve TrenibotE (trenibotulinumtoxinE), an anti-wrinkle therapy developed by the AbbVie ( ABBV ) unit, Allergan Aesthetics. In a statement late Thursday, AbbVie ( ABBV ) announced that the FDA issued a complete response letter in response to its Biologics License Application for TrenibotE, a ...
Michael Vi/iStock Editorial via Getty Images The U.S. Food and Drug Administration (FDA) has declined to approve TrenibotE (trenibotulinumtoxinE), an anti-wrinkle therapy developed by the AbbVie ( ABBV ) unit, Allergan Aesthetics. In a statement late Thursday, AbbVie ( ABBV ) announced that the FDA issued a complete response letter in response to its Biologics License Application for TrenibotE, a botulinum neurotoxin with a rapid onset of action and a short duration of effect. The Botox maker added that, according to the CRL, the FDA has not requested the company to conduct additional clinical studies or cited concerns over the safety or efficacy of TrenibotE. However, the regulator has sought additional information regarding manufacturing processes. “AbbVie is confident that it can address the FDA's comments promptly and expects to submit a thorough response in the coming months,” the company said, adding that regulatory reviews for TrenibotE are currently underway in overseas markets as expected. More on AbbVie AbbVie: Fairly Valued And Positioned For Growth AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade) AbbVie: Upside Potential And Dividends With Competent Portfolio Renewal AbbVie announces new $1.4B manufacturing campus in North Carolina AbbVie signs pain drug licensing deal with China’s Haisco
Brent advanced for a fifth straight day, climbing above $105 a barrel as the impasse between Washington and Tehran over how to proceed with talks to end their eight-week conflict carried on. The dollar was on course for its first weekly gain this month. Treasuries eased, with the 10-year yield one basis point lower at 4.32%. While markets have whipsawed on geopolitical risks, corporate profits hav...
Brent advanced for a fifth straight day, climbing above $105 a barrel as the impasse between Washington and Tehran over how to proceed with talks to end their eight-week conflict carried on. The dollar was on course for its first weekly gain this month. Treasuries eased, with the 10-year yield one basis point lower at 4.32%. While markets have whipsawed on geopolitical risks, corporate profits have remained strong. Nearly 80% of the US equity benchmark’s firms have beaten first-quarter earnings estimates so far, according to data compiled by Bloomberg. The Opening Trade has everything you need to know as markets open across Europe. With analysis you won't find anywhere else, we break down the biggest stories of the day and speak to top guests who have skin in the game. Hosted by Anna Edwards, Guy Johnson and Tom Mackenzie. (Source: Bloomberg)
Philip Rycroft says promises on issues from economics to immigration have not lived up to expectations Britain should start talking about rejoining the EU, according to a former senior civil servant who ran the Brexit department. Philip Rycroft, who was permanent secretary of the Department for Exiting the EU, said the “argument was there to be won” about going back into Europe, adding that a “cle...
Philip Rycroft says promises on issues from economics to immigration have not lived up to expectations Britain should start talking about rejoining the EU, according to a former senior civil servant who ran the Brexit department. Philip Rycroft, who was permanent secretary of the Department for Exiting the EU, said the “argument was there to be won” about going back into Europe, adding that a “clear-headed appraisal of what is in the country’s best interests” was needed. However, he said rejoining the bloc could be a “long and windy” road. Continue reading...
Ruslan Lytvyn/iStock via Getty Images By Zain Vawda USD/CHF Daily Chart: Building a Base Above Key Support The daily time frame shows USD/CHF ( USD:CHF ) in a recovery phase following the sharp sell-off witnessed in early 2026. After bottoming out near the 0.7600 handle, the pair has formed a series of higher lows, currently supported by an ascending trendline. Price action is currently sandwiched...
Ruslan Lytvyn/iStock via Getty Images By Zain Vawda USD/CHF Daily Chart: Building a Base Above Key Support The daily time frame shows USD/CHF ( USD:CHF ) in a recovery phase following the sharp sell-off witnessed in early 2026. After bottoming out near the 0.7600 handle, the pair has formed a series of higher lows, currently supported by an ascending trendline. Price action is currently sandwiched between the 50-day MA (0.7845) and the 100-day MA (0.7865). A daily candle close above the 100-day MA would be a significant bullish signal, suggesting a shift in medium-term momentum. However, the overhead 200-day MA at 0.7937 remains the "line in the sand" for bulls. Until that level is reclaimed, the overall daily structure remains cautious. The RSI is hovering around the 50 midline, indicating a lack of clear directional conviction at this stage. USD/CHF Daily Chart - April 24, 2026 (Source: TradingView) H4 Chart: Testing the Golden Cross Zone Moving down to the 4-hour chart, we see a more defined bullish structure. USD/CHF has successfully pushed above the 0.7828 horizontal support level, which previously acted as a ceiling during the consolidation in mid-April. Notably, the H4 chart shows the 100-period MA crossing above the 200-period MA, often a precursor to sustained bullish momentum. Price is currently testing the 200-period MA (0.7887). A sustained break above this level would open the door for a retest of the psychological 0.8000 resistance area. The RSI on this time frame is rising toward 65.00, suggesting there is still room for further upside before reaching overbought conditions. USD/CHF Four-Hour Chart - April 24, 2026 (Source: TradingView) H1 Chart: Intra-day Scenarios and Key Levels The 1-hour chart provides a granular view of the current breakout attempt. Price has found a foothold above all three major moving averages (50, 100, and 200), which are now beginning to fan out, supporting the bullish thesis. Potential Bullish Scenario: If USD/CHF can mainta...
Tim Robberts/DigitalVision via Getty Images Palantir Technologies’ ( PLTR ) bull case is based on a paradigm shift from a government-centric contractor to a scalable commercial AI platform, while at the same time becoming part of the infrastructure of the US military’s systems. Maven becoming a Pentagon program of record gives Palantir stable long-cycle revenue growth coming from government source...
Tim Robberts/DigitalVision via Getty Images Palantir Technologies’ ( PLTR ) bull case is based on a paradigm shift from a government-centric contractor to a scalable commercial AI platform, while at the same time becoming part of the infrastructure of the US military’s systems. Maven becoming a Pentagon program of record gives Palantir stable long-cycle revenue growth coming from government sources, while US revenue growth above 100% confirms the AIP flywheel is here. So, margin expansion combined with unmodeled government upside is now driving growth beyond already ambitious expectations. Palantir's Pentagon Breakthrough Just Changed the Game The most critical event for Palantir, in my view, over the past few days is the increased focus from the marketplace on the fact that its Maven Smart System will become a formal Pentagon program of record . That, of course, is far more important than a mere analyst downgrade or dip-buy article since it is taking Palantir's defense operations out of contract-by-contract and making it more institutional in nature. Reuters notes that this designation will guarantee Palantir long-term funding, simplify its adoption through the US military, and place its oversight under the Pentagon's Chief Digital and AI Office. This further emphasizes Palantir's dual strategy: growing quickly in the business world while at the same time embedding itself within the decision structure of the US military. Here, high profits and high switching costs will typically be found. In addition, Palantir has joined efforts to co-develop the software part of the $185 billion Golden Dome missile defense system , the largest defense technology contract under the Trump administration. The Rosenblatt estimates suggest that the Golden Dome contract alone can bring in billions in revenues to Palantir in phase one. The Quarter That Needs to Confirm Everything The Q1 2026 results due 4 May will be a critical validation check for the company. Expectations have been hig...
SLB press release ( SLB ): Q1 Non-GAAP EPS of $0.52 in-line. Revenue of $8.72B (+2.7% Y/Y) beats by $60M . Board approved quarterly cash dividend of $0.295 per share Shares -2% PM. More on SLB SLB: Cheap Valuation On Long-Term Fundamentals SLB: An Interesting Proposition SLB Q1 earnings preview: Earnings seen falling despite steady revenue growth SLB, Subsea7 to partner with Petronas on Suriname o...
SLB press release ( SLB ): Q1 Non-GAAP EPS of $0.52 in-line. Revenue of $8.72B (+2.7% Y/Y) beats by $60M . Board approved quarterly cash dividend of $0.295 per share Shares -2% PM. More on SLB SLB: Cheap Valuation On Long-Term Fundamentals SLB: An Interesting Proposition SLB Q1 earnings preview: Earnings seen falling despite steady revenue growth SLB, Subsea7 to partner with Petronas on Suriname oil and gas projects Seeking Alpha’s Quant Rating on SLB
Tim Robberts/DigitalVision via Getty Images Palantir Technologies’ ( PLTR ) bull case is based on a paradigm shift from a government-centric contractor to a scalable commercial AI platform, while at the same time becoming part of the infrastructure of the US military’s systems. Maven becoming a Pentagon program of record gives Palantir stable long-cycle revenue growth coming from government source...
Tim Robberts/DigitalVision via Getty Images Palantir Technologies’ ( PLTR ) bull case is based on a paradigm shift from a government-centric contractor to a scalable commercial AI platform, while at the same time becoming part of the infrastructure of the US military’s systems. Maven becoming a Pentagon program of record gives Palantir stable long-cycle revenue growth coming from government sources, while US revenue growth above 100% confirms the AIP flywheel is here. So, margin expansion combined with unmodeled government upside is now driving growth beyond already ambitious expectations. Palantir's Pentagon Breakthrough Just Changed the Game The most critical event for Palantir, in my view, over the past few days is the increased focus from the marketplace on the fact that its Maven Smart System will become a formal Pentagon program of record . That, of course, is far more important than a mere analyst downgrade or dip-buy article since it is taking Palantir's defense operations out of contract-by-contract and making it more institutional in nature. Reuters notes that this designation will guarantee Palantir long-term funding, simplify its adoption through the US military, and place its oversight under the Pentagon's Chief Digital and AI Office. This further emphasizes Palantir's dual strategy: growing quickly in the business world while at the same time embedding itself within the decision structure of the US military. Here, high profits and high switching costs will typically be found. In addition, Palantir has joined efforts to co-develop the software part of the $185 billion Golden Dome missile defense system , the largest defense technology contract under the Trump administration. The Rosenblatt estimates suggest that the Golden Dome contract alone can bring in billions in revenues to Palantir in phase one. The Quarter That Needs to Confirm Everything The Q1 2026 results due 4 May will be a critical validation check for the company. Expectations have been hig...
格里姆利表示,AI对人文学科而言并非威胁,而是一次厘清人类“独特价值”的机会。 当地时间25日,全新的牛津大学苏世民人文中心(Stephen A. Schwarzman Centre for the Humanities)将正式向公众开放。据介绍,这座建筑由美国黑石集团创始人苏世民(Stephen A. Schwarzman)捐资1.85亿英镑兴建,未来牛津大学音乐、英语语言与文学、历史、语言学等...
格里姆利表示,AI对人文学科而言并非威胁,而是一次厘清人类“独特价值”的机会。 当地时间25日,全新的牛津大学苏世民人文中心(Stephen A. Schwarzman Centre for the Humanities)将正式向公众开放。据介绍,这座建筑由美国黑石集团创始人苏世民(Stephen A. Schwarzman)捐资1.85亿英镑兴建,未来牛津大学音乐、英语语言与文学、历史、语言学等七个人文学科都将汇聚在此,还将引入人工智能(AI)伦理研究所、牛津互联网研究所及新博德利人文图书馆等。 与中国大学不同,牛津大学在校级之下设有四个学术分部,人文学部是其中之一,下辖古典学、英语语言与文学、历史、语言学、音乐、东方学等部院系所,是全球规模最大的人文学术单位之一。 值得一提的是,新中心展出了人工智能艺术家雷菲克·阿纳多尔(Refik Anadol)与安娜·里德勒(Anna Ridler)的数字艺术作品,将人工智能与人文研究的交汇推至公众视野。 这是否意味着牛津人文学科正在以一种全新的姿态回应AI时代的挑战?牛津大学人文学部负责人、英国学术院院士丹尼尔·M·格里姆利(Daniel M. Grimley)在接受第一财经记者独家专访时表示, AI对人文学科而言并非威胁,而是一次厘清人类“独特价值”的机会。同时,他称,人文学科不应处于应对全球挑战的边缘,而应站在中心。 第一财经:在你看来,新中心的核心使命是什么? 丹尼尔·格里姆利: 苏世民人文中心的核心使命,是为21世纪的人文学科搭建一个平台。它把我们的学习、教学与研究汇聚在一起,以新的方式探讨人类历史与文化的长河,同时也探索人文学科如何回应当代全球性挑战。 这里同时也是一座公共建筑,我们希望以创新的方式与更广泛的社区建立联结,共同思考如何应对这些挑战。 第一财经:中心邀请了多位AI艺术家进行表演和创作,这是否代表牛津人文学科正在走向更跨学科的方向? 丹尼尔·格里姆利: 在苏世民人文中心与我们合作的数字文化学者,确实在跨越学科边界方面做了非常出色的工作,无论是科学与档案馆藏之间,还是语言、视觉呈现与声音之间,都形成了富有成效的融合。 将这些不同学科聚集在一起,能够让我们深入探讨一些最根本性的问题:人类的能动性体现在哪里,如何珍视与保护它,以及如何负责任地、合乎伦理地运用AI,让它造福世界。 第一财经:在AI快速发展的背...